China's original new drug approved to treat recurrent metastatic advanced breast cancer

China News Service, March 12 (Reporter Chen Jing) Breast cancer is the number one malignant tumor that seriously threatens the health of women in the world.

The reporter was informed on the 12th that China's National Medical Products Administration (NMPA) officially approved China's original research drug-Uti Di? (Common name: Uti Delong) is used for the treatment of recurrent and metastatic advanced breast cancer.

It is reported that, thanks to the national policy of encouraging the creation of new drugs and accelerating the review and approval, Utidelon was listed as a national class I anti-tumor innovative drug and won the national "13th Five-Year Plan" major new drug creation project.

It is understood that for patients with advanced breast cancer, prolonging their survival period and improving their quality of life are the main treatment goals.

Professor Xu Binghe from the Cancer Hospital of theChinese Academy of Medical Sciences bluntly said in an interview with a reporter from Chinanews.

The results of a prospective, multi-center phase III clinical study showed that compared with capecitabine monotherapy for advanced breast cancer patients who have previously used anthracyclines and taxanes, they received Utidrolone combined with capecitata The overall survival period of the patients treated with steroids was significantly extended from 15.

The company revealed that it will continue to deepen the development of various new indications of UTI Delong, speed up the development of different dosage forms, use independent key technology platforms to promote the follow-up research and development of other innovative drugs with different targets, and plan to develop local research and development.